- Q3 revenue grew 64% YoY to $340.5M, driven by Korlym ($249.1M) and Lifyorli ($91.4M).
- Diluted EPS reached $1.01 compared to $0.16 in Q3 prior year; net income rose to $126.8M.
- Reconfirmed full-year 2026 revenue guidance of $1.1B to $1.2B; cash and investments stand at $662.3M.
Signal #119333 · SEC 8-K
$CORT SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $CORT filing catalyst
Why did $CORT trigger an AI stock catalyst alert?
$CORT triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.8/10). Headline: Corcept Therapeutics Reports Q3 Net Income of $126.8M, Diluted EPS Jumps to $1.01. Key points: - Q3 revenue grew 64% YoY to $340.5M, driven by Korlym ($249.1M) and Lifyorli ($91.4M). - Diluted EPS reached $1.01 compared to $0.16 in Q3 prior year; net income rose to $126.8M. - Reconfirmed full-year 2026 revenue guidance of $1.1B to $1.2B; cash and investments stand at $662.3M.
How did $CORT stock react after the SEC filing?
After the SEC 8-K for $CORT, observed market reaction: T0 price $81.93. Past moves do not guarantee future results.
Where can I get real-time $CORT SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CORT via Telegram and the VIP Web Terminal from €10/month.